Silymarin and its active component silibinin act as novel therapeutic alternatives for salivary gland cancer by targeting the ERK1/2-Bim signaling cascade
Crossref DOI link: https://doi.org/10.1007/s13402-017-0318-8
Published Online: 2017-04-11
Published Print: 2017-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Choi, Eun-Sun
Oh, Sejun
Jang, Boonsil
Yu, Hyun-Ju
Shin, Ji-Ae
Cho, Nam-Pyo
Yang, In-Hyoung
Won, Dong-Hoon
Kwon, Hye-Jeong
Hong, Seong Doo
Cho, Sung-Dae
License valid from 2017-04-11